New data from two phase 3 studies found that in patients with relapsing forms of multiple sclerosis (MS), the new anti-CD20 monoclonal antibody drug, ublituximab, is associated with significant ...
SALT LAKE CITY, Oct. 14, 2021 (GLOBE NEWSWIRE) — Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, presented positive results from the Phase 2 REPAIR-MS target engagement clinical ...
INDIANAPOLIS -- Daclizumab HYP (Zinbryta) may have an advantage over interferon-beta-1a (Avonex) in terms of patient-centered functional outcomes in multiple sclerosis (MS), researchers reported here.
Researchers have studied MS measurement tools for their effectiveness in predicting employment status. They compared the Expanded Disability Status Scale, the Multiple Sclerosis Functional Composite, ...
Disease severity also influences how these patients interact with and react to everyday stimuli. Multiple sclerosis (MS) is a chronic auto-immune disease that attacks the central nervous system, ...
Disease-modifying treatments (DMTs), which are the foundation of multiple sclerosis (MS) care, reduce clinical exacerbations (relapses) and slow disease progression; however, improving quality of life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results